CANGRELOR ZUR BEHANDLUNG UND/ODER PRÄVENTION VON SHUNT ODER STENTTHROMBOSE

European patent · EP3641784 · In force

Register entry

Publication number
EP3641784
Application number
EP18737821
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jun 22, 2018
Published
Apr 29, 2020
Granted
Mar 4, 2026
Protection ends at the latest
Jun 21, 2038
Next annual fee due
Jun 30, 2027
IPC classes
A61K 31/7076 (2006.01)
A61P 7/02 (2006.01)
A61P 9/04 (2006.01)
Priority
US 201762524102 P 23.06.2017
PCT application
PCT/EP2018/066817 22.06.2018
PCT publication
WO2018/234565 27.12.2018
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jul 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.06.2026 → 30.06.2027

    Published in Swissreg on 01.07.2026

  2. Mar 11, 2026

    Agent entered

    Representative
    Novagraaf International SA, Chemin de l'Echo 3, 1213 Onex

    Published in Swissreg on 11.03.2026

  3. Mar 4, 2026

    Granted

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 04.03.2026

Parties

Holder

Chiesi Farmaceutici S.p.A.

Via Palermo, 26/A, 43122 Parma, IT

Agent

Novagraaf International SA

Chemin de l'Echo 3, 1213 Onex

Inventor

DIACOVO, Thomas G.

43122 Parma, IT

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.